Shire Tweets ADHD education

Share this article:
Shire Tweets ADHD education
Shire Tweets ADHD education

Shire has launched an ADHD Support Twitter page ( to complement its unbranded education site

The Twitter feed, which boasts 186 followers, has been live, if sparsely updated, since October – mostly with links to and other ADHD education resources. The page advises visitors: “At this time, we aren't able to follow other users. You can provide comments toll free at the Shire Customer Service Center.”

As for its decision not to allow direct messaging through the feed, Shire spokesman Matt Cabrey told MM&M, that "Shire's approach at this time is to carefully manage the dissemination of information in a way that is consistent with existing industry regulatory guidelines, and we therefore have chosen to not offer a direct-messaging feature available through social media vehicles like Twitter."

The direct-messaging feature enables conversation about the disease state or treatment options. When that kind of dialogue begins to happen, industry would be required to disclose safety and prescribing information for the drugs being discussed. Social-media tools like Twitter do not allow for the level of detail needed to comply.

Topics to be covered by the Twitter page include the latest ADHD research, tips, resources and events of interest to the ADHD community, and the site may feature guest Tweeters.

“Extending our ADHD resources through Twitter is part of the ongoing commitment of Shire to provide education and support to patients and caregivers,” said Shire SVP, ADHD Business Unit Michael Yasick in a statement. “By providing access to information from via Twitter, we are able to reach people who are looking for ADHD information in untraditional yet increasingly popular places like social networking sites.”

The Twitter feed is not Shire's first use of social media. In May its GI team worked with the Crohn's & Colitis Foundation of America on an IBD-related awareness initiative called the “Virtual Walk.” The program was driven through Facebook.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...